{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"KALV","limit":50},"count":50,"signals":[{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":35,"context":"ed public accounting firm of the Company for its eight-month transition period ending December31, 2025; | | |  |  3. |  To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in this proxy statement; and | | |  |  4. |  To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. | | The foregoing","filed_date":"2025-08-21","accession":"0001193125-25-185353","full_text":"https://origin.rootz.global/static/filing/0001193125-25-185353.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"n, a potent hormone produced by plasma kallikrein, that activates its receptors on blood vessels to increase vascular leakage. Uncontrolled plasma kallikrein activity leads to the edema that is the hallmark of HAE. 6 While HAE most often results from the inheritance of a defective gene from a parent, it is estimated that up to 25% of cases also arise from spontaneous mutations. Patients with C1-INH-r","filed_date":"2025-07-10","accession":"0000950170-25-095011","full_text":"https://origin.rootz.global/static/filing/0000950170-25-095011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":71,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. 19 Europe / rest of world government regulation In addition to regulations in the U.S., we are","filed_date":"2025-07-10","accession":"0000950170-25-095011","full_text":"https://origin.rootz.global/static/filing/0000950170-25-095011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":34,"context":"independent registered public accounting firm of the Company for its fiscal year ending April 30, 2025; | | |  |  3. |  To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in this proxy statement; and | | |  |  4. |  To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. | | The foregoing","filed_date":"2024-08-22","accession":"0001193125-24-205356","full_text":"https://origin.rootz.global/static/filing/0001193125-24-205356.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"n, a potent hormone produced by plasma kallikrein, that activates its receptors on blood vessels to increase vascular leakage. Uncontrolled plasma kallikrein activity leads to the edema that is the hallmark of HAE. While HAE most often results from the inheritance of a defective gene from a parent, it is estimated that up to 25% of cases also arise from spontaneous mutations. Patients with C1-INH-rel","filed_date":"2024-07-11","accession":"0000950170-24-082965","full_text":"https://origin.rootz.global/static/filing/0000950170-24-082965.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":72,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. Europe / rest of world government regulation In addition to regulations in the U.S., we are su","filed_date":"2024-07-11","accession":"0000950170-24-082965","full_text":"https://origin.rootz.global/static/filing/0000950170-24-082965.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":30,"context":"independent registered public accounting firm of the Company for its fiscal year ending April 30, 2024; | | |  |  3. |  To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in this proxy statement; | | |  |  4. |  To approve an amendment to our Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as pe","filed_date":"2023-08-14","accession":"0001193125-23-212312","full_text":"https://origin.rootz.global/static/filing/0001193125-23-212312.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"study is time to beginning of symptom relief assessed using the PGI-C scale. KONFIDENT is being conducted in approximately 60 sites in 20 countries. In July 2023, we announced that we reached our enrollment target of 114 patients in the study and as a result we expect data from KONFIDENT in the fourth quarter of 2023. If the trial is successful, we anticipate submitting an NDA to the FDA in the first","filed_date":"2023-07-10","accession":"0000950170-23-032298","full_text":"https://origin.rootz.global/static/filing/0000950170-23-032298.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. Europe / rest of world government regulation In addition to regulations in the U.S., we are su","filed_date":"2023-07-10","accession":"0000950170-23-032298","full_text":"https://origin.rootz.global/static/filing/0000950170-23-032298.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"hich the Company is a party or by which any of its properties is bound, in each case except for breaches, violations and contraventions, if any, as would not, individually or in the aggregate, have a material adverse effect on the financial condition, results of operations, business, properties or assets of the Company (a **Material Adverse Effect**).  **5.3. Issuance of Shares.**Upon issuance to the Investor against re","filed_date":"2022-12-27","accession":"0001193125-22-312030","full_text":"https://origin.rootz.global/static/filing/0001193125-22-312030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"independent registered public accounting firm of the Company for its fiscal year ending April 30, 2023; | | |  |  3. |  To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in this proxy statement; | | |  |  4. |  To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. | | The foregoing ite","filed_date":"2022-08-22","accession":"0001193125-22-226471","full_text":"https://origin.rootz.global/static/filing/0001193125-22-226471.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"n, a potent hormone produced by plasma kallikrein, that activates its receptors on blood vessels to increase vascular leakage. Uncontrolled plasma kallikrein activity leads to the edema that is the hallmark of HAE. Selective plasma kallikrein inhibitors and a bradykinin receptor antagonist are approved therapies for HAE. As such, plasma kallikrein is a clinically validated target for HAE and previous","filed_date":"2022-07-07","accession":"0000950170-22-012521","full_text":"https://origin.rootz.global/static/filing/0000950170-22-012521.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. Europe / rest of world government regulation In addition to regulations in the United States,","filed_date":"2022-07-07","accession":"0000950170-22-012521","full_text":"https://origin.rootz.global/static/filing/0000950170-22-012521.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"independent registered public accounting firm of the Company for its fiscal year ending April 30, 2022; | | |  |  3. |  To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in this proxy statement; | | |  |  4. |  To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. | | The foregoing ite","filed_date":"2021-08-17","accession":"0001193125-21-249158","full_text":"https://origin.rootz.global/static/filing/0001193125-21-249158.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"n, a potent hormone produced by plasma kallikrein, that activates its receptors on blood vessels to increase vascular leakage. Uncontrolled plasma kallikrein activity leads to the edema that is the hallmark of HAE. Selective plasma kallikrein inhibitors and a bradykinin receptor antagonist are approved therapies for HAE. As such, plasma kallikrein is a clinically validated target for HAE and previous","filed_date":"2021-07-13","accession":"0001564590-21-036441","full_text":"https://origin.rootz.global/static/filing/0001564590-21-036441.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"educed Medicare payments to several providers, including hospitals and imaging centers. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our products, if approved, and, accordingly, our financial operations.  19 There has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in","filed_date":"2021-07-13","accession":"0001564590-21-036441","full_text":"https://origin.rootz.global/static/filing/0001564590-21-036441.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":47,"context":"independent registered public accounting firm of the Company for its fiscal year ending April 30, 2021; | | |  |  3. |  To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in this proxy statement; | | |  |  4. |  To select, on a non-binding advisory basis, whether future advisory votes on the compensation paid by us to our named executive officers should","filed_date":"2020-08-25","accession":"0001193125-20-229923","full_text":"https://origin.rootz.global/static/filing/0001193125-20-229923.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"n, a potent hormone produced by plasma kallikrein, that activates its receptors on blood vessels to increase vascular leakage. Uncontrolled plasma kallikrein activity leads to the edema that is the hallmark of HAE. Selective plasma kallikrein inhibitors and a bradykinin receptor antagonist are approved therapies for HAE. As such, plasma kallikrein is a clinically validated target for HAE and previous","filed_date":"2020-07-01","accession":"0001564590-20-031501","full_text":"https://origin.rootz.global/static/filing/0001564590-20-031501.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"educed Medicare payments to several providers, including hospitals and imaging centers. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our products, if approved, and, accordingly, our financial operations.  18 There has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in","filed_date":"2020-07-01","accession":"0001564590-20-031501","full_text":"https://origin.rootz.global/static/filing/0001564590-20-031501.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"educed Medicare payments to several providers, including hospitals and imaging centers. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our products, if approved, and, accordingly, our financial operations.  The Foreign Corrupt Practices Act  The Foreign Corrupt Practices Act (FCPA) prohibits any U.S. individual or b","filed_date":"2019-07-16","accession":"0001564590-19-025009","full_text":"https://origin.rootz.global/static/filing/0001564590-19-025009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"rship or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or other), earnings, business, properties, operations, assets, liabilities or prospects of the Company and its subsidiaries, considered as one entity (a **Material Adverse","filed_date":"2019-03-29","accession":"0001193125-19-092945","full_text":"https://origin.rootz.global/static/filing/0001193125-19-092945.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"educed Medicare payments to several providers, including hospitals and imaging centers. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our products, if approved, and, accordingly, our financial operations.  The Foreign Corrupt Practices Act  The Foreign Corrupt Practices Act (FCPA) prohibits any U.S. individual or b","filed_date":"2018-07-30","accession":"0001564590-18-017915","full_text":"https://origin.rootz.global/static/filing/0001564590-18-017915.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"ans any and all liabilities, obligations, costs and expenses or commitments of any nature whatsoever, accrued or fixed, absolute or contingent, matured or unmatured, or determined or determinable. (t)Material Adverse Effect means any event, occurrence, fact, condition or change that is, or would reasonably be expected to become, individually or in the aggregate, materially adverse to (i) the Program, the Purchased Asset","filed_date":"2017-12-14","accession":"0001564590-17-024944","full_text":"https://origin.rootz.global/static/filing/0001564590-17-024944.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"se and education and his experience gained through his board and officer positions at other life sciences companies.  9 THE BOARD OF DIRECTORS RECOMMENDS A VOTE  FOR THE ELECTION OF EACH OF THE ABOVE NAMED NOMINEES  Directors Continuing in Office Until the 2018 Annual Meeting of Stockholders  Albert Cha, M.D., Ph.D., has served as a member of KalVistas board of directors since the consummation of the Carbylan Therapeutic","filed_date":"2017-08-25","accession":"0001564590-17-018076","full_text":"https://origin.rootz.global/static/filing/0001564590-17-018076.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"educed Medicare payments to several providers, including hospitals and imaging centers. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our products, if approved, and, accordingly, our financial operations.  The Foreign Corrupt Practices Act  The Foreign Corrupt Practices Act (FCPA) prohibits any U.S. individual or b","filed_date":"2017-07-27","accession":"0001564590-17-014286","full_text":"https://origin.rootz.global/static/filing/0001564590-17-014286.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"plicable laws, orders, rules, regulations and directives issued or administered by such jurisdictions, except where the failure to be in compliance would not, individually or in the aggregate, have a Material Adverse Effect (as defined below).  (g) Foreign Qualification of the Company. The Company is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction where the ownership o","filed_date":"2017-07-13","accession":"0001193125-17-227682","full_text":"https://origin.rootz.global/static/filing/0001193125-17-227682.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"tory agencies prior to commercial sales. There can be no assurance that any product candidates will receive the necessary approvals and any failure to receive approval or delay in approval may have a material adverse impact on the business and financial statements of the Company. The Company has never been profitable and has not yet commenced commercial operations. KalVista is subject to a number of risks and uncertaint","filed_date":"2017-03-16","accession":"0001564590-17-004659","full_text":"https://origin.rootz.global/static/filing/0001564590-17-004659.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"ficer and our two other most highly compensated executive officers who were serving as executive officers as of April 30, 2016. The persons listed in the following table are referred to herein as the named executive officers. Because SEC rules require us to disclose this information as of the end of our last fiscal year, and because our acquisition of KalVista Limited took place in November 2016, this executive compensa","filed_date":"2017-03-02","accession":"0001193125-17-067690","full_text":"https://origin.rootz.global/static/filing/0001193125-17-067690.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"further clinical development of Hydros-TA and that it was actively pursuing a strategic transaction, including a merger or acquisition of the Company. In April 2016, the board of directors approved a restructuring plan effective as of April15, 2016 resulting in a reduction in force affecting 14 of the Companys 17 employees, including two executive officers. The restructuring plan was intended to reduce operational","filed_date":"2016-11-08","accession":"0001564590-16-028340","full_text":"https://origin.rootz.global/static/filing/0001564590-16-028340.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":14,"context":"further clinical development of Hydros-TA and that it is actively pursuing a strategic transaction, including a merger or acquisition of the Company. In April 2016, the board of directors approved a restructuring plan effective as of April15, 2016 resulting in a reduction in force affecting 14 of the Companys 17 employees, including two executive officers. The restructuring plan is intended to reduce operational c","filed_date":"2016-08-12","accession":"0001564590-16-024180","full_text":"https://origin.rootz.global/static/filing/0001564590-16-024180.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"Amounts shown represent the cash paid by us to Vivo Capital, LLC for consulting services performance in fiscal year 2015. Dr. Cha is a managing member of Vivo Capital, LLC. | | |  (3) |  Mr. Saul was appointed to our board of directors in February 1, 2016, so he did not receive any compensation in fiscal year 2015. | | 28  [Table of Contents](#toc) **EXECUTIVE OFFICERS** The following is biographical information for our current ex","filed_date":"2016-04-28","accession":"0001193125-16-563716","full_text":"https://origin.rootz.global/static/filing/0001193125-16-563716.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"ction or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.  7 FDA approval is required before any new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States. The process required by the","filed_date":"2016-03-30","accession":"0001564590-16-015646","full_text":"https://origin.rootz.global/static/filing/0001564590-16-015646.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"sales. There can be no assurance that the Companys current and future product candidates will receive the necessary approvals. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Companys business and its financial statements. The Company is subject to risks common to companies in the pharmaceutical industry with no commercial operating history, including, but not limi","filed_date":"2015-11-12","accession":"0001564590-15-010631","full_text":"https://origin.rootz.global/static/filing/0001564590-15-010631.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"sales. There can be no assurance that the Companys current and future product candidates will receive the necessary approvals. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Companys business and its financial statements. The Company is subject to risks common to companies in the pharmaceutical industry with no commercial operating history, including, but not limi","filed_date":"2015-08-13","accession":"0001564590-15-007264","full_text":"https://origin.rootz.global/static/filing/0001564590-15-007264.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"sales. There can be no assurance that the Companys current and future product candidates will receive the necessary approvals. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Companys business and its financial statements.  The Company is subject to risks common to companies in the pharmaceutical industry with no commercial operating history, including, but not lim","filed_date":"2015-05-21","accession":"0001193125-15-196884","full_text":"https://origin.rootz.global/static/filing/0001193125-15-196884.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":30,"context":"ussions, we are enrolling our COR1.1 trial and preparing to enroll our COR1.2 trial, based upon the following study designs:  |  |  |  |  COR1.1: The first of our two pivotal Phase 3 trials began enrollment in mid-January 2014. We are actively enrolling up to 510 subjects (of which approximately 350 patients have been enrolled as of March 31, 2015) at approximately 30 sites in Australia, Canada, New","filed_date":"2015-04-06","accession":"0001193125-15-119335","full_text":"https://origin.rootz.global/static/filing/0001193125-15-119335.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"cause undesirable side effects or have other properties that could delay our clinical trials, or delay or prevent regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if any. If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product candidate, the abil","filed_date":"2015-04-06","accession":"0001193125-15-119335","full_text":"https://origin.rootz.global/static/filing/0001193125-15-119335.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":27,"context":"ired in June 2014, and Hayley Lewis, our vice president of regulatory affairs and quality assurance, who was hired in May 2014. These executives are collectively referred to in this prospectus as our named executive officers.  Each year, the compensation committee of our board of directors and our board of directors review and determine the compensation of our named executive officers.  This discussion contains forward","filed_date":"2015-04-06","accession":"0001193125-15-119335","full_text":"https://origin.rootz.global/static/filing/0001193125-15-119335.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":37,"context":"ussions, we are enrolling our COR1.1 trial and preparing to enroll our COR1.2 trial, based upon the following study designs:  |  |  |  |  COR1.1: The first of our two pivotal Phase 3 trials began enrollment in mid-January 2014. We are actively enrolling up to 510 subjects at 30 to 40 sites in Australia, Canada, New Zealand, Europe and the Caribbean. Subjects with OA grade two and grade three are rand","filed_date":"2014-12-29","accession":"0001193125-14-455475","full_text":"https://origin.rootz.global/static/filing/0001193125-14-455475.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"cause undesirable side effects or have other properties that could delay our clinical trials, or delay or prevent regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if any. If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product candidate, the abil","filed_date":"2014-12-29","accession":"0001193125-14-455475","full_text":"https://origin.rootz.global/static/filing/0001193125-14-455475.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":", Samuel Lynch, who held those roles in 2013, from the time of Mr. Daniloffs resignation in April to Mr. Renzis hiring in June. These executives are collectively referred to in this prospectus as our named executive officers. In June 2014, we hired T. Michael White to serve as our vice president of finance and chief financial officer. Because he was hired after the close of fiscal year 2013, Mr. White is not a named exe","filed_date":"2014-12-29","accession":"0001193125-14-455475","full_text":"https://origin.rootz.global/static/filing/0001193125-14-455475.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"n, a potent hormone produced by plasma kallikrein, that activates its receptors on blood vessels to increase vascular leakage. Uncontrolled plasma kallikrein activity leads to the edema that is the hallmark of HAE. A selective plasma kallikrein inhibitor and a bradykinin receptor antagonist are approved therapies for HAE. As such, plasma kallikrein is a clinically validated target for HAE and previou","filed_date":"2018-07-30","accession":"0001564590-18-017915","full_text":"https://origin.rootz.global/static/filing/0001564590-18-017915.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":96,"match_count":12,"context":"further clinical development of Hydros-TA and that it is actively pursuing a strategic transaction, including a merger or acquisition of the Company.  In April 2016, the board of directors approved a restructuring plan effective as of April15, 2016 resulting in a reduction in force affecting 14 of the Companys 17 employees, including two executive officers. The restructuring plan is intended to reduce operational c","filed_date":"2016-05-12","accession":"0001564590-16-019244","full_text":"https://origin.rootz.global/static/filing/0001564590-16-019244.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"come (expense), net. Maintenance and repairs are charged to operations as incurred. Pre-clinical and Clinical Trial Accruals The Companys clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with clinical research organizations that conduct and man","filed_date":"2015-11-12","accession":"0001564590-15-010631","full_text":"https://origin.rootz.global/static/filing/0001564590-15-010631.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"come (expense), net. Maintenance and repairs are charged to operations as incurred. Pre-clinical and Clinical Trial Accruals The Companys clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with clinical research organizations that conduct and man","filed_date":"2015-08-13","accession":"0001564590-15-007264","full_text":"https://origin.rootz.global/static/filing/0001564590-15-007264.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"(expense), net. Maintenance and repairs are charged to operations as incurred.  **Pre-clinical and Clinical Trial Accruals** The Companys clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with clinical research organizations that conduct and man","filed_date":"2015-05-21","accession":"0001193125-15-196884","full_text":"https://origin.rootz.global/static/filing/0001193125-15-196884.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"n, a potent hormone produced by plasma kallikrein, that activates its receptors on blood vessels to increase vascular leakage. Uncontrolled plasma kallikrein activity leads to the edema that is the hallmark of HAE. Selective plasma kallikrein inhibitors and a bradykinin receptor antagonist are approved therapies for HAE. As such, plasma kallikrein is a clinically validated target for HAE and previous","filed_date":"2019-07-16","accession":"0001564590-19-025009","full_text":"https://origin.rootz.global/static/filing/0001564590-19-025009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"ced by plasma kallikrein, that activates its receptors on blood vessels to increase vascular leakage. Uncontrolled plasma kallikrein activity leads to the tissue inflammation and edema that are the hallmarks of HAE. As such, plasma kallikrein is a clinically validated target for HAE and previous studies have demonstrated that plasma kallikrein inhibition can both treat and prevent HAE attacks.  3 Cur","filed_date":"2017-07-27","accession":"0001564590-17-014286","full_text":"https://origin.rootz.global/static/filing/0001564590-17-014286.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"may differ from these estimates under different assumptions or conditions. Preclinical and Clinical Trial Accruals We base our accrued expenses related to clinical trials on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for services received and efforts expended pursuant to contracts with multiple research institutions and contract research","filed_date":"2017-03-16","accession":"0001564590-17-004659","full_text":"https://origin.rootz.global/static/filing/0001564590-17-004659.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KALV","company":"KalVista Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":70,"match_count":5,"context":"tory agencies prior to commercial sales. There can be no assurance that any product candidates will receive the necessary approvals and any failure to receive approval or delay in approval may have a material adverse impact on the business and financial statements of the sponsoring company. If the Companys strategic transaction with KalVista is not consummated and it decides to continue its historical business operation","filed_date":"2016-11-08","accession":"0001564590-16-028340","full_text":"https://origin.rootz.global/static/filing/0001564590-16-028340.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"bc5b1c81005b45811b84c7c4e57a193b680db21123b6d8a4bad48da282b9ec8a","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"dffb2185b033d584fa537ddf6338b8535a0f5d602f5c54f2f230b8b694db92d4","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":490,"hourly_limit":500,"remaining":10,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}